人群结直肠癌筛查意味着使用粪便免疫化学试验检测血红蛋白（FIT）进行 FIT：结直肠癌筛查的过去、现在和未来。
Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).
机构信息
Division of Gastroenterology, University of California San Francisco School of Medicine, San Francisco, CA, USA. ; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Centre for Research into Cancer Prevention and Screening, University of Dundee School of Medicine, Dundee, Scotland.
出版信息
Gut Liver. 2014 Mar;8(2):117-30. doi: 10.5009/gnl.2014.8.2.117. Epub 2014 Mar 11.
Fecal immunochemical tests for hemoglobin (FIT) are changing the manner in which colorectal cancer (CRC) is screened. Although these tests are being performed worldwide, why is this test different from its predecessors? What evidence supports its adoption? How can this evidence best be used? This review addresses these questions and provides an understanding of FIT theory and practices to expedite international efforts to implement the use of FIT in CRC screening.
粪便免疫化学检测血红蛋白（FIT）正在改变结直肠癌（CRC）的筛查方式。尽管这些检测在全球范围内都在进行，但为什么这项检测与之前的检测不同？有哪些证据支持其采用？如何最好地利用这些证据？本综述旨在回答这些问题，并深入了解 FIT 的理论和实践，以加速国际上采用 FIT 进行 CRC 筛查的努力。
Zotero 插件